Associations of plasma NfL, GFAP, and t-tau with cerebral small vessel disease and incident dementia: longitudinal data of the AGES-Reykjavik Study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Associations of plasma NfL, GFAP, and t-tau with cerebral small vessel disease and incident dementia: longitudinal data of the AGES-Reykjavik Study ; day:2 ; month:8 ; year:2023 ; pages:1-12
GeroScience ; (2.8.2023), 1-12
- Urheber
-
Gennip, April C. E. van
Satizabal, Claudia L.
Tracy, Russell P.
Sigurdsson, Sigurdur
Gudnason, Vilmundur
Launer, Lenore J.
Sloten, Thomas T. van
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11357-023-00888-1
- URN
-
urn:nbn:de:101:1-2023110109023652685158
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gennip, April C. E. van
- Satizabal, Claudia L.
- Tracy, Russell P.
- Sigurdsson, Sigurdur
- Gudnason, Vilmundur
- Launer, Lenore J.
- Sloten, Thomas T. van
- SpringerLink (Online service)
Ähnliche Objekte (12)
NFL and GFAP in (pre)symptomatic RVCL-S carriers: a monogenic cerebral small vessel disease
Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank
Association of serum GFAP with functional and neurocognitive outcome in sporadic small vessel disease
Plasma NfL, GFAP, amyloid, and p-tau species as Prognostic biomarkers in Parkinson’s disease
Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting
GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA)
Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias
Central nervous system biomarkers GFAp and NfL associate with post-acute cognitive impairment and fatigue following critical COVID-19
An innovative approach for the evaluation of prolonged disorders of consciousness using NF-L and GFAP biomarkers: a pivotal study
Das Gliafaserprotein (GFAP) in Hirntumoren
Entopallium Lost GFAP Immunoreactivity during Avian Evolution: Is GFAP a “Condition Sine Qua Non”?
N.F.L. Porth
NFL and GFAP in (pre)symptomatic RVCL-S carriers: a monogenic cerebral small vessel disease
Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank
Association of serum GFAP with functional and neurocognitive outcome in sporadic small vessel disease
Plasma NfL, GFAP, amyloid, and p-tau species as Prognostic biomarkers in Parkinson’s disease
Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting
GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA)
Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias
Central nervous system biomarkers GFAp and NfL associate with post-acute cognitive impairment and fatigue following critical COVID-19
An innovative approach for the evaluation of prolonged disorders of consciousness using NF-L and GFAP biomarkers: a pivotal study
Das Gliafaserprotein (GFAP) in Hirntumoren
Entopallium Lost GFAP Immunoreactivity during Avian Evolution: Is GFAP a “Condition Sine Qua Non”?
N.F.L. Porth
NFL and GFAP in (pre)symptomatic RVCL-S carriers: a monogenic cerebral small vessel disease
Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank
Association of serum GFAP with functional and neurocognitive outcome in sporadic small vessel disease
Plasma NfL, GFAP, amyloid, and p-tau species as Prognostic biomarkers in Parkinson’s disease
Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting
GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA)
Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias
Central nervous system biomarkers GFAp and NfL associate with post-acute cognitive impairment and fatigue following critical COVID-19
An innovative approach for the evaluation of prolonged disorders of consciousness using NF-L and GFAP biomarkers: a pivotal study
Das Gliafaserprotein (GFAP) in Hirntumoren
Entopallium Lost GFAP Immunoreactivity during Avian Evolution: Is GFAP a “Condition Sine Qua Non”?